nach oben

Erschienen in:

01.06.2019 | Original Article

Volume-based glucose metabolic analysis of FDG PET/CT: The optimum threshold and conditions to suppress physiological myocardial uptake

verfasst von: Osamu Manabe, MD, PhD, Markus Kroenke, MD, Tadao Aikawa, MD, Atsuto Murayama, MSc, Masanao Naya, MD, PhD, Atsuro Masuda, MD, PhD, Noriko Oyama-Manabe, MD, PhD, Kenji Hirata, MD, PhD, Shiro Watanabe, MD, PhD, Tohru Shiga, MD, PhD, Chietsugu Katoh, MD, PhD, Nagara Tamaki, MD, PhD

Erschienen in: Journal of Nuclear Cardiology | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Objective

FDG PET/CT plays a significant role in the diagnosis of inflammatory heart diseases and cardiac tumors. We attempted to determine the optimal FDG uptake threshold for volume-based analyses and to evaluate the relationship between the myocardial physiological uptake volume in FDG PET and several clinical factors.

Methods

A total of 190 patients were retrospectively analyzed. The cardiac metabolic volume (CMV) was defined as a volume within the boundary determined by a threshold (SUVmean of blood pool × 1.5).

Results

The SUVmean of the blood pool measured in the descending aorta (DA) (r = 0.86, intraclass correlation coefficient [ICC] = 0.93, P < 0.0001) and that in the left ventricle (LV) cavity (r = 0.87, ICC = 0.90, P < 0.0001) showed high inter-operator reproducibility. However, the SUVmean in the LV cavity showed a significant correlation with the CMV (P = 0.0002, r = 0.26). The CMV in the patients who fasted < 18 hours were significantly higher (49.7 ± 73.2 vs. 18.0 ± 53.8 mL, P = 0.0013) compared to the patients with > 18-hour fasting. The multivariate analysis demonstrated that only the fasting period > 18 hours was independently associated with CMV = 0.

Conclusion

Our findings revealed that the DA is suitable to decide the threshold for the volume-based analysis. The fasting time was significantly associated with the cardiac FDG uptake.

Nur mit Berechtigung zugänglich

Manabe O, Yoshinaga K, Ohira H, et al. The effects of 18-h fasting with low-carbohydrate diet preparation on suppressed physiological myocardial (18)F-fluorodeoxyglucose (FDG) uptake and possible minimal effects of unfractionated heparin use in patients with suspected cardiac involvement sarcoidosis. J Nucl Cardiol. 2016;23:244–52.CrossRefPubMed

Hyun SH, Choi JY, Shim YM, et al. Prognostic value of metabolic tumor volume measured by ¹⁸F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma. Ann Surg Oncol. 2010;17:115–22.CrossRefPubMed

Burger IA, Casanova R, Steiger S, et al. ¹⁸F-FDG PET/CT of non-small cell lung carcinoma under neoadjuvant chemotherapy: background-based adaptive-volume metrics outperform TLG and MTV in predicting histopathologic response. J Nucl Med. 2016;57:849–54.CrossRefPubMed

Ohira H, Mc Ardle B, de Kemp RA, et al. Inter- and intra- observer agreement of FDG-PET/CT image interpretation in patients referred for assessment of Cardiac Sarcoidosis. J Nucl Med. 2017;58:1324–9.CrossRefPubMed

Manabe O, Ohira H, Yoshinaga K, Naya M, Oyama-Manabe N, Tamaki N. Qualitative and quantitative assessments of cardiac sarcoidosis using ¹⁸F-FDG PET. Ann Nucl Cardiol. 2017;3:125–30.CrossRef

Ahmadian A, Brogan A, Berman J, et al. Quantitative interpretation of FDG PET/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis. J Nucl Cardiol. 2014;21:925–39.CrossRefPubMed

Masuda A, Naya M, Manabe O, et al. Administration of unfractionated heparin with prolonged fasting could reduce physiological ¹⁸F-fluorodeoxyglucose uptake in the heart. Acta Radiol. 2016;57:661–8.CrossRefPubMed

Blomberg BA, Bashyam A, Ramachandran A, et al. Quantifying [(1)(8)F]fluorodeoxyglucose uptake in the arterial wall: the effects of dual time-point imaging and partial volume effect correction. Eur J Nucl Med Mol Imaging. 2015;42:1414–22.CrossRefPubMed

Choi Y, Hawkins RA, Huang SC, et al. Evaluation of the effect of glucose ingestion and kinetic model configurations of FDG in the normal liver. J Nucl Med. 1994;35:818–23.PubMed

10.

Ishida Y, Yoshinaga K, Miyagawa M, et al. Recommendations for (18)F-fluorodeoxyglucose positron emission tomography imaging for cardiac sarcoidosis: Japanese Society of Nuclear Cardiology recommendations. Ann Nucl Med. 2014;28:393–403.CrossRefPubMed

11.

Hirata K, Kobayashi K, Wong KP, et al. A semi-automated technique determining the liver standardized uptake value reference for tumor delineation in FDG PET-CT. PloS ONE. 2014;9:e105682.CrossRefPubMedPubMedCentral

12.

Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50:122S–50S.CrossRefPubMed

13.

Kaneta T, Hakamatsuka T, Takanami K, et al. Evaluation of the relationship between physiological FDG uptake in the heart and age, blood glucose level, fasting period, and hospitalization. Ann Nucl Med. 2006;20:203–8.CrossRefPubMed

14.

Morooka M, Moroi M, Uno K, et al. Long fasting is effective in inhibiting physiological myocardial ¹⁸F-FDG uptake and for evaluating active lesions of cardiac sarcoidosis. EJNMMI Res. 2014;4:1.CrossRefPubMedPubMedCentral

15.

Youssef G, Leung E, Mylonas I, et al. The use of ¹⁸F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. J Nucl Med. 2012;53:241–8.CrossRefPubMed

16.

Israel O, Weiler-Sagie M, Rispler S, et al. PET/CT quantitation of the effect of patient-related factors on cardiac ¹⁸F-FDG uptake. J Nucl Med. 2007;48:234–9.PubMed

17.

Manabe O, Yoshinaga K, Ohira H, et al. The effects of 18-h fasting with low-carbohydrate diet preparation on suppressed physiological myocardial F-fluorodeoxyglucose (FDG) uptake and possible minimal effects of unfractionated heparin use in patients with suspected cardiac involvement sarcoidosis. J Nucl Cardiol. 2015;23:244–52.CrossRefPubMedPubMedCentral

18.

Keramida G, Potts J, Bush J, Dizdarevic S, Peters AM. Hepatic steatosis is associated with increased hepatic FDG uptake. Eur J Radiol. 2014;83:751–5.CrossRefPubMed

19.

Osborne MT, Hulten EA, Singh A, et al. Reduction in (1)(8)F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis. J Nucl Cardiol. 2014;21:166–74.CrossRefPubMed

20.

Ito K, Okazaki O, Morooka M, Kubota K, Minamimoto R, Hiroe M. Visual findings of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with cardiac sarcoidosis. Intern Med. 2014;53:2041–9.CrossRefPubMed

21.

de Groot M, Meeuwis AP, Kok PJ, Corstens FH, Oyen WJ. Influence of blood glucose level, age and fasting period on non-pathological FDG uptake in heart and gut. Eur J Nucl Med Mol Imaging. 2005;32:98–101.CrossRefPubMed

22.

Miyagawa M, Tashiro R, Watanabe E, et al. Optimal patient preparation for detection and assessment of cardiac sarcoidosis by FDG-PET. Ann Nucl Cardiol. 2017;3:113–6.CrossRef

23.

Ohira H, Tsujino I, Yoshinaga K. (1)(8)F-Fluoro-2-deoxyglucose positron emission tomography in cardiac sarcoidosis. Eur J Nucl Med Mol Imaging. 2011;38:1773–83.CrossRefPubMed

Titel: Volume-based glucose metabolic analysis of FDG PET/CT: The optimum threshold and conditions to suppress physiological myocardial uptake
verfasst von: Osamu Manabe, MD, PhD
Markus Kroenke, MD
Tadao Aikawa, MD
Atsuto Murayama, MSc
Masanao Naya, MD, PhD
Atsuro Masuda, MD, PhD
Noriko Oyama-Manabe, MD, PhD
Kenji Hirata, MD, PhD
Shiro Watanabe, MD, PhD
Tohru Shiga, MD, PhD
Chietsugu Katoh, MD, PhD
Nagara Tamaki, MD, PhD
Publikationsdatum: 01.06.2019
Verlag: Springer International Publishing
Erschienen in: Journal of Nuclear Cardiology / Ausgabe 3/2019
Print ISSN: 1071-3581
Elektronische ISSN: 1532-6551
DOI: https://doi.org/10.1007/s12350-017-1122-6

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Objective

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2019

Assessment of left ventricular mass by SPECT MPI

Myocardial perfusion imaging for cardiac allograft vasculopathy assessment: Evidence grows, but questions remain

Myocardial perfusion imaging in non-ischemic cardiomyopathy

Social media update: The launch of @JNCjournal

Impact of regadenoson-induced myocardial creep on dynamic Rubidium-82 PET myocardial blood flow quantification